Transrectal ultrasound (TRUS) guided 12 core biopsy of prostate has a sensitivity of 39-52%. We prospectively evaluated the role of DWI in guiding MRI-TRUS fusion biopsy. MRI was performed on a 3 Tesla system. PIRAD score was assigned and PIRAD 3-5 score were subjected to targeted fusion biopsy using the Artemis device along with standard 12 core biopsies. Targeted biopsy detected a higher number (93%) of clinically significant cancers and 71% cancers were upgraded to significant cancer on targeted biopsy. Fusion biopsies guided by DWI thus provide incremental information over standard TRUS biopsies in the diagnosis of significant prostate cancer.
This abstract and the presentation materials are available to members only; a login is required.